Justin Walsh, an analyst from JonesTrading, has initiated a new Buy rating on VolitionRX (VNRX).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Justin Walsh has given his Buy rating due to a combination of factors that highlight VolitionRx’s promising future. The company is strategically positioned in the epigenetics field, utilizing nucleosomes and transcription factors to enhance diagnostic and monitoring capabilities. Their Nu.Q assays, protected by patents, are set to gain traction through collaborations with significant partners in both human and animal health sectors. This strategy is expected to lead to favorable operating margins, with projections of 85% by 2034, driven by a 22% royalty rate for human health assets.
Moreover, the potential for VolitionRx’s assays in sepsis and lung cancer prognosis is particularly promising, offering clinical benefits without directly competing with existing market solutions. The anticipated partnership in the human health domain is seen as a crucial catalyst for the company’s growth, providing both non-dilutive capital and validation of their business strategy. With groundwork already laid in Europe through direct sales, and conservative estimates in animal health, Walsh sees significant upside potential, justifying the Buy rating.
Walsh covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Achieve Life Sciences, and Actinium Pharmaceuticals. According to TipRanks, Walsh has an average return of -1.8% and a 34.15% success rate on recommended stocks.